Harvard Bioscience (HBIO) Inventory (2010 - 2026)

Harvard Bioscience (HBIO) has reported Inventory for 17 consecutive years, with $22.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory changed 0.11% year-over-year to $22.2 million in Q2 2026; TTM through Jun 2026 was $22.2 million, a 0.11% change from a year earlier, with the FY2025 full-year figure at $20.8 million, down 10.5% from the prior year.
• Inventory was $22.2 million for Q2 2026 at Harvard Bioscience, roughly flat from $22.2 million in the prior quarter.
• Over five years, Inventory peaked at $29.3 million in Q2 2022 and troughed at $20.8 million in Q4 2025.
• A 5-year average of $24.7 million and a median of $24.9 million in 2023 frame the typical range for Inventory.
• Across the five-year window, Inventory increased 26.61% in 2022 and dropped 16.88% in 2025, its largest moves.
• Over 5 years, Inventory stood at $26.4 million in 2022, then fell by 6.52% to $24.7 million in 2023, then dropped by 5.95% to $23.2 million in 2024, then decreased by 10.5% to $20.8 million in 2025, then gained by 6.85% to $22.2 million in 2026.
• The last three Inventory figures came in at $22.2 million (Q2 2026), $22.2 million (Q1 2026), and $20.8 million (Q4 2025), per Business Quant data.